Free Trial

Veracyte Q1 2023 Earnings Report

Veracyte logo
$39.18 -1.87 (-4.56%)
As of 02/21/2025 04:00 PM Eastern

Veracyte EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$0.20

Veracyte Revenue Results

Actual Revenue
$82.40 million
Expected Revenue
$75.75 million
Beat/Miss
Beat by +$6.65 million
YoY Revenue Growth
+21.50%

Veracyte Announcement Details

Quarter
Q1 2023
Time
After Market Closes

VCYT Upcoming Earnings

Veracyte will be holding an earnings conference call on Monday, February 24 at 4:30 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Veracyte Earnings Headlines

Veracyte, Inc.
Analysts Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $42.00
“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
Veracyte to Participate in Upcoming Investor Conferences
Veracyte (NASDAQ:VCYT) Lowered to "Hold" Rating by StockNews.com
See More Veracyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email.

About Veracyte

Veracyte (NASDAQ:VCYT) engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

View Veracyte Profile

More Earnings Resources from MarketBeat